Interventions to increase COVID-19 vaccine uptake: a scoping review.

Marike Andreas, Claire Iannizzi, Emma Bohndorf, Ina Monsef, Vanessa Piechotta, Joerg J Meerpohl, Nicole Skoetz
Author Information
  1. Marike Andreas: Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  2. Claire Iannizzi: Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  3. Emma Bohndorf: Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  4. Ina Monsef: Faculty of Medicine and University Hospital Cologne, University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cochrane Haematology, Cologne, Germany.
  5. Vanessa Piechotta: Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  6. Joerg J Meerpohl: Institute for Evidence in Medicine (for Cochrane Germany Foundation), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  7. Nicole Skoetz: Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Abstract

BACKGROUND: Vaccines are effective in preventing severe COVID-19, a disease for which few treatments are available and which can lead to disability or death. Widespread vaccination against COVID-19 may help protect those not yet able to get vaccinated. In addition, new and vaccine-resistant mutations of SARS-CoV-2 may be less likely to develop if the spread of COVID-19 is limited. Different vaccines are now widely available in many settings. However, vaccine hesitancy is a serious threat to the goal of nationwide vaccination in many countries and poses a substantial threat to population health. This scoping review maps interventions aimed at increasing COVID-19 vaccine uptake and decreasing COVID-19 vaccine hesitancy.
OBJECTIVES: To scope the existing research landscape on interventions to enhance the willingness of different populations to be vaccinated against COVID-19, increase COVID-19 vaccine uptake, or decrease COVID-19 vaccine hesitancy, and to map the evidence according to addressed populations and intervention categories.
SEARCH METHODS: We searched Cochrane COVID-19 Study Register, Web of Science (Science Citation Index Expanded and Emerging Sources Citation Index), WHO COVID-19 Global literature on coronavirus disease, PsycINFO, and CINAHL to 11 October 2021.
SELECTION CRITERIA: We included studies that assess the impact of interventions implemented to enhance the willingness of different populations to be vaccinated against COVID-19, increase vaccine uptake, or decrease COVID-19 vaccine hesitancy. We included randomised controlled trials (RCTs), non-randomised studies of intervention (NRSIs), observational studies and case studies with more than 100 participants. Furthermore, we included systematic reviews and meta-analyses. We did not limit the scope of the review to a specific population or to specific outcomes assessed. We excluded interventions addressing hesitancy towards vaccines for diseases other than COVID-19.
DATA COLLECTION AND ANALYSIS: Data were analysed according to a protocol uploaded to the Open Science Framework. We used an interactive scoping map to visualise the results of our scoping review. We mapped the identified interventions according to pre-specified intervention categories, that were adapted to better fit the evidence. The intervention categories were: communication interventions, policy interventions, educational interventions, incentives (both financial and non-financial), interventions to improve access, and multidimensional interventions. The study outcomes were also included in the mapping. Furthermore, we mapped the country in which the study was conducted, the addressed population, and whether the design was randomised-controlled or not.
MAIN RESULTS: We included 96 studies in the scoping review, 35 of which are ongoing and 61 studies with published results. We did not identify any relevant systematic reviews. For an overview, please see the interactive scoping map (https://tinyurl.com/2p9jmx24) STUDIES WITH PUBLISHED RESULTS Of the 61 studies with published results, 46 studies were RCTs and 15 NRSIs. The interventions investigated in the studies were heterogeneous with most studies testing communication strategies to enhance COVID-19 vaccine uptake. Most studies assessed the willingness to get vaccinated as an outcome. The majority of studies were conducted in English-speaking high-income countries. Moreover, most studies investigated digital interventions in an online setting. Populations that were addressed were diverse. For example, studies targeted healthcare workers, ethnic minorities in the USA, students, soldiers, at-risk patients, or the general population.  ONGOING STUDIES Of the 35 ongoing studies, 29 studies are RCTs and six NRSIs. Educational and communication interventions were the most used types of interventions. The majority of ongoing studies plan to assess vaccine uptake as an outcome. Again, the majority of studies are being conducted in English-speaking high-income countries. In contrast to the studies with published results, most ongoing studies will not be conducted online. Addressed populations range from minority populations in the USA to healthcare workers or students. Eleven ongoing studies have estimated completion dates in 2022.   AUTHORS' CONCLUSIONS: We were able to identify and map a variety of heterogeneous interventions for increasing COVID-19 vaccine uptake or decreasing vaccine hesitancy. Our results demonstrate that this is an active field of research with 61 published studies and 35 studies still ongoing. This review gives a comprehensive overview of interventions to increase COVID-19 vaccine uptake and can be the foundation for subsequent systematic reviews on the effectiveness of interventions to increase COVID-19 vaccine uptake.  A research gap was shown for studies conducted in low and middle-income countries and studies investigating policy interventions and improved access, as well as for interventions addressing children and adolescents. As COVID-19 vaccines become more widely available, these populations and interventions should not be neglected in research.
AUTHORS CONCLUSIONS: We were able to identify and map a variety of heterogeneous interventions for increasing COVID-19 vaccine uptake or decreasing vaccine hesitancy. Our results demonstrate that this is an active field of research with 61 published studies and 35 studies still ongoing. This review gives a comprehensive overview of interventions to increase COVID-19 vaccine uptake and can be the foundation for subsequent systematic reviews on the effectiveness of interventions to increase COVID-19 vaccine uptake.  A research gap was shown for studies conducted in low and middle-income countries and studies investigating policy interventions and improved access, as well as for interventions addressing children and adolescents. As COVID-19 vaccines become more widely available, these populations and interventions should not be neglected in research.

References

  1. Health Commun. 2022 Jul;37(8):944-951 [PMID: 33499677]
  2. Vaccines (Basel). 2022 Jan 04;10(1): [PMID: 35062738]
  3. AIDS Behav. 2020 Oct;24(10):2776-2780 [PMID: 32440972]
  4. PLoS One. 2020 May 14;15(5):e0232652 [PMID: 32407329]
  5. Psychol Med. 2023 May;53(7):3242-3244 [PMID: 34538287]
  6. PLoS One. 2022 Aug 5;17(8):e0272426 [PMID: 35930557]
  7. PLoS One. 2022 May 19;17(5):e0267580 [PMID: 35587462]
  8. J Health Commun. 2020 Oct 2;25(10):838-842 [PMID: 33719882]
  9. Cochrane Database Syst Rev. 2020 Jan 17;1:CD011895 [PMID: 31978259]
  10. Nat Rev Microbiol. 2021 Jul;19(7):406 [PMID: 34017089]
  11. Am J Transplant. 2021 Apr;21(4):1650-1656 [PMID: 33788992]
  12. J Law Biosci. 2021 Sep 06;8(2):lsab027 [PMID: 34512996]
  13. J Med Libr Assoc. 2006 Oct;94(4):451-5 [PMID: 17082841]
  14. Anaesth Crit Care Pain Med. 2021 Jun;40(3):100860 [PMID: 33848874]
  15. Vaccine. 2023 Oct 6;41(42):6300-6308 [PMID: 37679277]
  16. Proc Natl Acad Sci U S A. 2021 Sep 7;118(36): [PMID: 34413212]
  17. Lancet Public Health. 2021 Jun;6(6):e416-e427 [PMID: 33991482]
  18. Nat Hum Behav. 2021 Mar;5(3):337-348 [PMID: 33547453]
  19. J Health Econ. 2022 Jan;81:102578 [PMID: 34986437]
  20. Health Commun. 2023 Jan;38(1):152-159 [PMID: 34114897]
  21. Ecohealth. 2021 Mar;18(1):44-60 [PMID: 34086129]
  22. JAMA Netw Open. 2021 Sep 1;4(9):e2126635 [PMID: 34591105]
  23. Int J Environ Res Public Health. 2021 Aug 20;18(16): [PMID: 34444549]
  24. JAMA Oncol. 2021 Oct 1;7(10):1570-1572 [PMID: 34410323]
  25. Elife. 2022 Aug 16;11: [PMID: 35971757]
  26. Public Health. 2021 Dec;201:98-107 [PMID: 34801843]
  27. PLoS One. 2021 Mar 24;16(3):e0248892 [PMID: 33760836]
  28. Patient Educ Couns. 2022 Feb;105(2):284-289 [PMID: 34479746]
  29. JAMA. 2021 Aug 24;326(8):766-767 [PMID: 34213530]
  30. Proc Natl Acad Sci U S A. 2021 Jan 5;118(1): [PMID: 33443183]
  31. Am J Med. 2021 Nov;134(11):1424-1426 [PMID: 34339676]
  32. Vaccine. 2015 Aug 14;33(34):4180-90 [PMID: 25896377]
  33. Hum Vaccin Immunother. 2015;11(1):72-82 [PMID: 25483518]
  34. Appl Psychol Health Well Being. 2021 Nov;13(4):986-995 [PMID: 34032388]
  35. BMC Med Res Methodol. 2018 Nov 19;18(1):143 [PMID: 30453902]
  36. PLoS One. 2022 Jan 24;17(1):e0260949 [PMID: 35073312]
  37. Soc Sci Med. 2021 Nov;289:114416 [PMID: 34562773]
  38. Hum Vaccin Immunother. 2021 Sep 2;17(9):2940-2945 [PMID: 33998949]
  39. Cochrane Database Syst Rev. 2018 May 08;5:CD010038 [PMID: 29736980]
  40. Soc Sci Med. 2020 Oct;263:113356 [PMID: 32967786]
  41. Health Commun. 2023 Apr;38(4):813-823 [PMID: 34544315]
  42. J Health Commun. 2021 Sep 2;26(9):608-617 [PMID: 34596481]
  43. Hum Vaccin Immunother. 2021 Sep 2;17(9):2894-2902 [PMID: 33877955]
  44. Eur J Epidemiol. 2021 Jul;36(7):709-714 [PMID: 34037927]
  45. Cochrane Database Syst Rev. 2022 Aug 3;8:CD015270 [PMID: 35920693]
  46. Vaccines (Basel). 2021 Sep 30;9(10): [PMID: 34696221]
  47. Health Commun. 2023 Apr;38(4):732-741 [PMID: 34474607]
  48. Vaccines (Basel). 2021 May 24;9(6): [PMID: 34073757]
  49. Int J Environ Res Public Health. 2021 Apr 28;18(9): [PMID: 33924796]
  50. Vaccines (Basel). 2021 Feb 16;9(2): [PMID: 33669441]
  51. Int J Health Policy Manag. 2022 Jul 1;11(7):1090-1101 [PMID: 33619928]
  52. Vaccine. 2021 Jan 29;39(5):825-829 [PMID: 33390295]
  53. BMC Med Inform Decis Mak. 2021 Jul 31;21(1):228 [PMID: 34332570]
  54. JAMA Netw Open. 2021 Jul 1;4(7):e2118702 [PMID: 34319359]
  55. Eur J Intern Med. 2021 May;87:106-108 [PMID: 33810941]
  56. Science. 2021 Nov 12;374(6569):879-882 [PMID: 34618594]
  57. Vaccine. 2015 Aug 14;33(34):4191-203 [PMID: 25896385]
  58. Health Res Policy Syst. 2008 Jul 09;6:7 [PMID: 18613961]
  59. J Med Ethics. 2021 Aug;47(8):547-548 [PMID: 33602717]
  60. Health Psychol. 2015 Feb;34(2):160-71 [PMID: 25133822]
  61. EClinicalMedicine. 2021 May 15;35:100881 [PMID: 34124631]
  62. Infect Control Hosp Epidemiol. 2022 Sep;43(9):1201-1206 [PMID: 34287112]
  63. Proc Natl Acad Sci U S A. 2021 Mar 9;118(10): [PMID: 33619178]
  64. Vaccines (Basel). 2021 Sep 07;9(9): [PMID: 34579232]
  65. Vaccine. 2014 Apr 17;32(19):2150-9 [PMID: 24598724]
  66. Int J Environ Res Public Health. 2021 Sep 08;18(18): [PMID: 34574406]
  67. J Community Health. 2021 Dec;46(6):1155-1160 [PMID: 33988777]
  68. Health Psychol. 2022 Feb;41(2):85-93 [PMID: 34570535]
  69. Int J Clin Pract. 2021 Apr;75(4):e13891 [PMID: 33278857]
  70. J Health Commun. 2021 Aug 3;26(8):523-533 [PMID: 34424140]
  71. Ann Intern Med. 2018 Oct 2;169(7):467-473 [PMID: 30178033]
  72. Vaccines (Basel). 2021 May 17;9(5): [PMID: 34067682]
  73. Trials. 2021 Apr 29;22(1):311 [PMID: 33926540]
  74. Value Health. 2021 Nov;24(11):1543-1550 [PMID: 34711354]
  75. PLoS One. 2021 Sep 27;16(9):e0257988 [PMID: 34570798]
  76. NPJ Vaccines. 2021 May 14;6(1):73 [PMID: 33990614]
  77. JMIR Res Protoc. 2021 May 13;: [PMID: 34086594]
  78. Pan Afr Med J. 2021 Jan 05;38:3 [PMID: 33520072]
  79. Cochrane Database Syst Rev. 2018 May 30;5:CD005188 [PMID: 29845606]
  80. Vacunas. 2021 May-Aug;22(2):93-97 [PMID: 33727904]
  81. Vaccines (Basel). 2021 Apr 13;9(4): [PMID: 33924534]
  82. J Exp Psychol Appl. 2021 Dec;27(4):669-678 [PMID: 34292048]
  83. J Public Health (Oxf). 2022 Mar 7;44(1):e106-e116 [PMID: 33948665]
  84. Proc Natl Acad Sci U S A. 2021 Aug 10;118(32): [PMID: 34312254]
  85. Psychol Sci Public Interest. 2017 Dec;18(3):149-207 [PMID: 29611455]
  86. BMJ Open. 2022 Sep 7;12(9):e051352 [PMID: 36691187]
  87. Nat Hum Behav. 2021 Mar;5(3):407 [PMID: 33686205]
  88. Vaccine. 2022 Jul 30;40(32):4654-4662 [PMID: 35750541]
  89. PLoS One. 2021 Sep 20;16(9):e0257111 [PMID: 34543291]
  90. Pediatrics. 2014 Oct;134(4):e1117-28 [PMID: 25225138]
  91. Cochrane Database Syst Rev. 2016 Jul 10;7:CD008145 [PMID: 27394698]
  92. Vaccines (Basel). 2021 Jul 07;9(7): [PMID: 34358173]
  93. Psychol Med. 2022 Oct;52(14):3127-3141 [PMID: 33305716]
  94. Ann Behav Med. 2022 Apr 2;56(4):325-331 [PMID: 34398184]
  95. Syst Dyn Rev. 2022 Jul-Sep;38(3):246-263 [PMID: 36245852]
  96. BMJ. 2021 May 13;373:n1088 [PMID: 33985964]
  97. Cochrane Database Syst Rev. 2018 Jan 18;1:CD003941 [PMID: 29342498]
  98. Public Health. 2021 May;194:245-251 [PMID: 33965796]
  99. Hum Vaccin Immunother. 2021 Oct 3;17(10):3450-3456 [PMID: 34128754]
  100. Am J Manag Care. 2007 Oct;13(10):581-8 [PMID: 17927463]
  101. Lancet Public Health. 2021 Apr;6(4):e210-e221 [PMID: 33556325]
  102. Proc Natl Acad Sci U S A. 2021 Aug 10;118(32): [PMID: 34315824]
  103. Vaccines (Basel). 2021 Apr 13;9(4): [PMID: 33924542]
  104. Br J Health Psychol. 2022 May;27(2):300-319 [PMID: 34250684]
  105. PLoS One. 2022 Mar 30;17(3):e0263425 [PMID: 35353815]
  106. Nature. 2021 Sep;597(7876):404-409 [PMID: 34340242]
  107. PLoS One. 2022 Jan 19;17(1):e0258828 [PMID: 35045071]
  108. Trials. 2021 Sep 06;22(1):592 [PMID: 34488843]
  109. Health Educ Res. 2011 Apr;26(2):192-200 [PMID: 21106651]
  110. Hum Vaccin Immunother. 2021 Aug 3;17(8):2415-2420 [PMID: 34014128]
  111. Healthcare (Basel). 2021 Mar 19;9(3): [PMID: 33808758]

MeSH Term

Adolescent
COVID-19
COVID-19 Vaccines
Child
Health Personnel
Humans
Randomized Controlled Trials as Topic
SARS-CoV-2
Vaccination

Chemicals

COVID-19 Vaccines